TABLE V. Characteristics of sequence-types (ST) detected among clinical and environmental study isolates.
| Isolate | Antimicrobial resistance Profile | ST | CC | Countries |
|---|---|---|---|---|
| Clinical Isolates | ||||
|
| ||||
| PCI032 | AMK, FEP, CIP, CAZ, TZP, TOB, GEN | 1844 | Singleton | Brazil |
| PCI042 | MEM, FEP, CIP, IPM, CAZ, TZP, TOB, GEN | 244 | 244 | Australia, Central African Republic, China, France, Ivory Coast, Nigeria, Poland, Russia, Spain, UK |
| PCI045 | Susceptible | 235 | 235 | Australia, Belarus, Brazil, Central African Republic, China, Croatia, France, Hungary, Ivory Coast, Kazakhstan, Nigeria, Norway, Poland, Republic of Belarus, Russia, Serbia, Singapore, Spain |
| PCI124 | MEM, AMK, FEP, CIP, IPM, TZP, TOB, GEN | |||
| PCI059 | IPM | 890 | Singleton | Australia, Brazil |
| PCI073 | Susceptible | 1767 | 244 | Brazil |
| PCI126 | Susceptible | 532 | 244 | Australia, Brazil, France, Spain |
| PCI133 | Susceptible | 1027 | SLV of 2223 | Brazil |
| PCC457 | MEM, FEP, CIP, IPM, CAZ, TZP, TOB, GEN | 1768 | 244 | Brazil |
| PCC524 | FEP | 1769 | 195 | Brazil |
| PCC762 | MEM, AMK, FEP, CIP, IPM, CAZ, TOB, GEN | 1602 | SLV of ST1937 | Brazil |
|
| ||||
| Environmental isolates | ||||
|
| ||||
| CTI9.2B | AMK, CAZ, FEP, GEN, IPM, CIP, TOB | 1602 | SLV of ST1937 | Brazil |
| CTI9.2A | AMK, CAZ, FEP, GEN, IPM, CIP, TOB | 1603 | 244 | Brazil |
| CTI19 | Susceptible | 446 | 244 | Australia, Brazil, France, Spain |
| CTI33 | CAZ, FEP, GEN, IPM, MEM, CIP, TOB | 277 | 244 | Australia, Austria, Brazil, China, Central African Republic, Spain |
AMK: amikacin; CAZ: ceftazidime; CIP: ciprofloxacin; FEP: cefepime; GEN: gentamicin; IPM: imipenem; MEM: meropenem; TZP: piperacillin-tazobactam; TOB: tobramycin; SLV: single-locus variant.